Premium
Efficacy and pharmacokinetics of piretanide in patients with congestive heart failure
Author(s) -
MARONE C.,
RIVERA B.,
ZWAHLEN H.,
LAHN W.,
FREY F.
Publication year - 1989
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/j.1365-2362.1989.tb00245.x
Subject(s) - diuresis , medicine , diuretic , heart failure , pharmacokinetics , renal function , furosemide , excretion , urology , pharmacology
. The efficacy and pharmacokinetics of the diuretic piretanide were studied in two groups of six patients hospitalized for congestive heart failure. A dosage of 2 times 6 mg day ‐1 to 2 times 12 mg day ‐1 of intravenous piretanide for 7 days was sufficient to abrogate most symptoms of cardiac insufficiency. When compared with another group of healthy volunteers, patients with congestive heart failure had reduced total body clearance of piretanide of about 50% which was attributable to a diminished renal but not non‐renal clearance. The analysis of the interrelationship between urinary piretanide excretion and diuresis by means of a linearized E max ‐model revealed a maximal diuresis of 231 ml h ‐1 and a urinary piretanide excretion to induce half‐maximal diuresis of 245 μg h ‐1 . Thus patients with congestive heart failure exhibit a decreased renal clearance of piretanide and a good response to this high ceiling diuretic after intravenous dosing.